CancerVax

OUR TEAM

Byron Horton Elton

President, CEO and Principal Accounting Officer

Byron Elton has served as our director since December 16, 2022 and our President and CEO since February 1, 2024. Mr. Elton is an experienced media and marketing executive with a proven record in pioneering new business development strategies and building top-flight marketing organizations. Since June 2018, he has been President of Elton Enterprises, Inc., which is involved in the wellness, fitness and health sectors. Mr. Elton is also the owner of certain StretchLab franchises. He is a co-founder since June 2017 of Pardue Associates, operating monsho, a brand-centric, creative communications agency focused on delivering results. From 2013 to 2017, Mr. Elton was a partner of Clear Search, an executive search firm. Prior to that, from 2009 until 2013, Mr. Elton served as President and Chief Executive Officer of Carbon Sciences, Inc., a cleantech company developing a technology to convert earth destroying carbon dioxide into a useful form. Mr. Elton previously served as Senior Vice President of Sales for Univision Online from 2007 to 2008. Mr. Elton also served for eight years as an executive at AOL Media Networks from 2000 to 2007, where his assignments included Regional Vice President of Sales for AOL and Senior Vice President of E-Commerce for AOL Canada. His broadcast media experience includes leading the ABC affiliate in Santa Barbara, California from 1995 to 2000 and the CBS affiliate in Monterrey, California from 1998 to 1999, in addition to serving as President of the Alaskan Television Network from 1995 to 1999. Mr. Elton studied Advertising and Marketing Communications at Brigham Young University.

George Edwin Katibah

PhD, Chief Scientific Officer

Expert in the discovery, development, and translation of novel therapies across diverse therapeutic modalities Part of teams that developed the first-in-human drug candidates, including small molecule STING agonists and personalized cancer neoantigen vaccine Co-authored more than 16 scientific papers and inventor on 3 issued U.S. patents and multiple pending applications Formerly Director of Discovery Biology at RAPT Therapeutics Formerly Senior Scientist and Head of Biochemistry at Aduro Biotech B.S. in Plant Sciences from the University of California, Santa Cruz PhD in Molecular and Cell Biology from the University of California, Berkeley"

Adam Grant

PhD, Principal Scientist

An inventor of the Company’s Universal Cancer Treatment platform. Expert computational biologist using next generation sequencing data to identify new drug targets and biomarkers of response to cancer therapeutics/ Formerly Bioinformatician at Xenter Medical Technologies/Formerly Computational Scientist at RAPT Therapeutics. Invented software to improve cancer antigen detection. Invented a gene-signature approach to select treatment for breast cancer. Received his B.S in Bioinformatics from Brigham Young University. Received his PhD in Cancer Biology with an emphasis in Bioinformatics from the University of Arizona

Sumant Ramachandra

MD, PhD, MBA, Chief Scientific Advisor

Sumant Ramachandra serves as an Independent Director on the Board of Lyell Immunopharma (“Lyell”), following Lyell’s acquisition of ImmPACT Bio (“ImmPACT”) in October 2024. As CEO of ImmPACT from November 2021 until its acquisition, he led capital raises, secured clinical grants, and built a team that achieved FDA clearance for three Investigational New Drug (IND) applications, established manufacturing capabilities, and advanced multiple clinical studies. In addition, Dr. Ramachandra currently serves as an advisor to private equity funds on companies in the pharmaceuticals, biotechnology, and medical devices/software spaces. Previously, Dr. Ramachandra served as Chief Science, Technology, and Medical Officer at Baxter International, starting in June 2017. He was also appointed President of Baxter Pharmaceuticals in 2019. Prior to Baxter, he held the role of Senior Vice President, Head of Research & Development, at Pfizer Essential Health, and served as Chief Scientific Officer at Hospira from 2008 until Pfizer acquired Hospira in 2015. Earlier in his career, Dr. Ramachandra held senior roles at Pfizer and Merck & Co., specializing in oncology, global product development, medical affairs, business development, and clinical pharmacology. He began his medical career as an intern and resident physician at Massachusetts General Hospital, Harvard Medical School. Dr. Ramachandra earned his undergraduate degree in biochemistry, a PhD in experimental pathology (with a focus on chronic lymphocytic leukemia), and an MD from Rutgers University. He also holds an MBA from the Wharton School, University of Pennsylvania.

Gordon Ringold

PhD, Strategic Advisor

Dr. Gordon Ringold is currently CEO of Quadriga BioSciences, a clinical phase cancer biotech company developing a novel L-type Amino Acid Transporter 1 (LAT1) for delivering chemotherapeutic agents across the blood brain barrier and into rapidly growing cancer cells. He is also the Founder and Executive Chairman of Maxymune, a biopharma company developing differentiated treatments to transform the lives of those affected by serious immunological diseases. He is currently on the board of directors of Okava Pharmaceuticals. From 1997 to 2015, he served in various capacities as Co-Founder and/or CEO of Maxygen, SurroMed, Alexza, and Alavita. From 1991 to 2000, Dr. Ringold was CEO and Scientific Director of Affymax Research Institute (acquired by Glaxo in 1995) where he managed the development of novel technologies to accelerate the pace of drug discovery; prior to that he was VP and Director of the Institute for Cancer and Developmental Biology at Syntex Corporation (1986-1991). Dr. Ringold received his Ph.D. in the laboratory of Dr. Harold Varmus (University of California, San Francisco), before joining the Stanford University School of Medicine, Department of Pharmacology (1978-1987). While on the Stanford faculty he invented technologies for manufacturing of recombinant proteins in mammalian cells, now widely used for production of dozens of therapeutic products and received the John J. Abel Award as the best Pharmacologist in the US under the age of 35. Dr. Ringold is an alumnus of Crown College, University of California, Santa Cruz, 1972.

Mark Davis

Senior Scientific Advisor

Mark M. Davis, PhD. is the Director of the Stanford Institute for Immunology, Transplantation and Infection (ITI), which has become an international leader in the development of transformative technologies and approaches to better understand the human immune system and its responses to infectious diseases and autoimmunity. He also serves as a Professor of Microbiology and Immunology at Stanford and is a Howard Hughes Medical Institute Investigator. Dr. Davis is well known for identifying the first T-cell receptor genes, which are responsible for T lymphocytes ability to “see” foreign pathogens, such as viruses, solving a major mystery in immunology at that time. He and his research group have made many subsequent discoveries about this type of molecule, demonstrating that T-cells are able to detect and respond to even a single molecule of their ligand-fragments of antigens bound to Major Histocompatibility Complex cell surface molecules. He also developed a novel way of labeling specific T lymphocytes according to the molecules that they recognize, and this procedure is now an important method in many clinical and basic studies of T-cell activity, as are other technologies developed by his group. According to research.com, Dr. Davis has authored over 680 publications with over 110,000 citations. He has received numerous awards and honors for his work, including memberships in the National Academy of Sciences, The National Academy of Medicine and the Royal Society.

George Kemble

Senior Scientific Advisor

George Kemble, PhD is a veteran biotech executive and scientist with a specialty focus in the areas of virology, vaccines and small molecule biologics. Dr. Kemble is currently the Chairman of the Board at Sagimet Biosciences Inc. (NASDAQ: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors for cancer treatment, liver fibrosis, acne and other diseases. He joined Sagimet in August 2011 as its chief scientific officer and served as CEO from October 2015 until October 2022, when he transitioned to the role of executive chairman. In May 2025, Dr. Kemble moved into the role of non-executive Chair of the Board. At Sagimet, he directed medicinal chemistry, research, translational and CMC groups, and worked on several programs including the lead product candidate, denifanstat.Prior to Sagimet, Dr. Kemble served as the senior vice president of R&D and head of research at MedImmune, Inc., a subsidiary of AstraZeneca PLC. During his tenure, he was responsible for a large group of scientists dedicated to the research and development of programs across a number of therapeutic areas, including the launch of FluMist®, the first innovation in influenza vaccines in over 60 years. Dr. Kemble received a BS degree from the University of Santa Clara, a PhD from Stanford University and completed post-doctoral training at UCSF, where he worked on various human viruses.

Amit Indap

PhD, Scientific Advisor

Expert in immuno-oncology involving mRNA vaccine development for cancer and COVID, CDx development using comprehensive genomic profiling of tumors, ctDNA analysis of clinical samples, NGS based antibody discovery, and single cell RNAseq analysis. Formerly Principal Scientist at Pfizer. Formerly Scientist at Good Start Genetics. Formerly Research Scientist at Human Longevity, Inc. Formerly Bioinformatics Scientist at Illumina. Formerly Senior Manager of Bioinformatics at Xencor. Received his B.S. in Molecular and Cellular Biology and minor in Computer Science From University of Arizona. Received his M.S. degree in bioinformatics from Medical College of Wisconsin. Received his PhD in Biology from Boston College

Jonathan Lakey

PhD, Scientific Advisor

An inventor of the famous “Edmonton Protocol” for treating Type 1 diabetes. Extensive experience in the fields of oncology, stem cells, and organ transplantation. Currently Professor Emeritus at University of California, Irvine. Formerly Postdoctoral Fellow, Cryobiology Research Institute Indiana University Indianapolis. Formerly Postdoctoral Fellow, Clinical tissue banking University of Washington. Formerly Postdoctoral Fellow, Tissue banking/cryopreservation University of Alberta. Published over 495 scientific papers, 45 books, and over 500 scientific abstracts. Advisor to many biotech companies. Received his BS in Zoology/Animal Biology from University of Alberta. Received his MS in Zoology/Animal Biology from University of Alberta. Received his PhD of Islet transplantation, diabetes, and medical devices from University of Alberta

Matthew Spear

PhD, Scientific Advisor

Expert in guiding the development and commercialization of new drugs, therapies, and biotech products as Chief Development Officer and Chief Medical Officer of biotech companies. Dr. Spear has been working in oncology and gene therapy research and development for over 30 years. Currently Chief Development Officer / Chief Medical Officer at Denovo Biopharma. Formerly Associate Professor on the faculty of the USC Keck School of Medicine, and the UCSD Medical School / UCSD Cancer Center where he managed a clinical practice, drug discovery/gene therapy research, and clinical trial programs for cancer. Formerly led multiple oncology clinical development programs at Pfizer. Formerly served as Chief Medical Officer and Senior Vice-President at Nereus Pharmaceuticals. Formerly Head of Oncology and Head of Biotherapeutics at Sunovion Pharmaceuticals. Formerly Vice-President at Incyte and Sangamo Therapeutics. Formerly Chief Medical Officer at Poseida Therapeutics developing multiple CAR-T cell and gene therapy products. Received a B.A. degree from the Johns Hopkins University. Received his M.D. degree from Stanford University

Steven Warner

PhD, Scientific Advisor

Specializes in small molecule drug discovery, new screening platforms in drug discovery, and translational research focusing on cancer therapeutics. He is an expert in the discovery of novel cancer agents and has played integral roles in moving multiple compounds into clinical trials. Currently Senior VP and Head of US Research at Sumitomo Pharma America. Formerly Manager of Discovery Biology at SuperGen. Formerly Senior Manager of Drug Discovery at Huntsman Cancer Institute. Formerly VP of Drug Discovery at Tolero Pharmaceuticals. Received his B.S. in Biology from Brigham Young University. Received his PhD in Pharmaceutical Sciences from the University of Arizona

Carla Jo Miller

Controller and Director

Carla Miller has served as our director since August 2021 and was appointed as our Controller on February 1, 2024. Ms. Miller is an accounting and business manager with years of experience working for and consulting to technology and financial services companies. Since 2009, she has been the Business Manager of Digital Locations, Inc., a publicly traded company focused on wireless communication. Prior to that, she was an Accounting Manager at Hub International Insurance, a provider of property, casualty, risk management, life and health, employee benefits, investment, and wealth management products and services across North America. Ms. Miller graduated from Platt College in St. Joseph, MO where she studied Accounting and Business Management."

Bradford Douglas Pearce

Director

Brad Pearce’s professional journey is marked by diverse achievements across sports, business, and leadership. Mr. Pearce was appointed Director of the Board of CancerVax on October 2, 2024. Since February 2025, Mr. Pearce has served on the Board of the Southern California Junior Tennis Foundation. In July 2024, Mr. Pearce expanded his business pursuits by becoming a Managing Director at Two Harbors Capital, an investment fund. Since 2020, Mr. Pearce has served as Vice President of Marketing for a leading US staffing firm. His strategic insights contributed significantly to the company's growth, helping revenue surge from $300 million to nearly $1 billion by the end of 2024. From 2000 to 2019 Mr. Pearce served as the Head Men’s Tennis Coach at Brigham Young University (BYU). During his nearly two-decade tenure, he elevated the program to national prominence, leading the team to numerous accolades and securing the unique achievement of endowing all scholarships in the men’s tennis program, a first in college sports. Mr. Pearce’s career began as a professional tennis player from 1986 to 1995, during which he secured 10 titles, earned a US Davis Cup appearance, defeated six former world #1 players, and made a notable run to the Wimbledon singles quarterfinals. After retiring from professional tennis, Brad transitioned into the technology and sales and marketing sectors, working for various firms from 1996 to 1999. Mr. Pearce’s career progression illustrates his ability to thrive in diverse fields, leveraging his competitive spirit, leadership skills, and strategic thinking across both sports and business.

Andrew Lewis Van Noy

Chief Operations Officer

Andrew Van Noy is a seasoned executive having been CEO of multiple companies in both the public and private markets. His operational expertise includes fundraising, marketing, business management and investor relations. He joined the company in February of 2024.

PERKS

earn bonus shares^*

Your belief in our vision deserves more, and in recognition of that support, we are extending a limited-time package of premium perks.

Loyalty Bonus: Investors in CancerVax as of May. 1, 2026 at 12:59 AM MDT, including individuals waitlisted in our offering that ended on April 30, 2026, will receive 20% bonus shares.

Time-Based Perks (Available for the First 14 Days of the Offering Only):

$1,000+
EARLY Tier 1

Invest $1,000 or more within the first 14 days and receive 10% bonus shares.